It's a really good announcement, Stroke is absolute mega potential and I believe they will wait for the super cash flows from Vitiligo to progress stroke into a mega blockbuster phase 3 (which will cost big bucks) - just like they are using EPP to pay for blockbuster Vitiligo phase 3. Rosenfeld knows more about Stroke and potential here than anyone reading this announcement does. To me it's a shame they don't put more resources into this now by hiring a few more scientists and pushing this along just like the Parkinson's Phase 2 trial. Seems strange to have 3 investor relations experts on 3 continents when Europe and US have basically zero trades each night and they can't get a valuation anywhere near their closest comparison stock in Disc who are burning $1 Million cash every 2 days and going nowhere fast. Manipulation is very easy with small companies on the ASX that are extremely heavily shorted each and every day, despite Clinuvel being the absolute best financially performing small/tiny Biotech year after year, and managing to keep growing profits while running a Phase 3 with an already FDA/EMA approved drug that will totally transform this company.
All IMO DYOR
CUV Price at posting:
$11.75 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)